Pelelisa 0.01

Pelelisa 0.01 | INDICATIONS AND USES

Tapinarof 1% cream is indicated for the topical treatment of plaque psoriasis in adult.

Pelelisa 0.01 | PHARMACOLOGY

This cream contains Tapinarof as the active ingredient. Tapinarof is an Aryl hydrocarbon Receptor (AhR) agonist. The specific mechanisms by which Tapinarof cream exerts its therapeutic action in psoriasis patients are unknown.

Pelelisa 0.01 | DOSAGE & ADMINISTRATION

Apply a thin layer of Tapinarof cream to affected areas once daily. Wash hands after application, unless Tapisis cream is for treatment of the hands. Tapinarof cream is not for oral, ophthalmic, or intravaginal use.Pediatric Use: Safety and efficacy of Tapinarof cream have not been established in pediatric subjects with psoriasis under 18 years of age.

Pelelisa 0.01 | DRUG INTERACTIONS

No hazardous interactions have been reported with other medicines.

Pelelisa 0.01 | SIDE EFFECTS

Most common adverse reactions (incidence ≥ 1%) in subjects treated with Tapisis cream were folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza.

Pelelisa 0.01 | USE DURING PREGNANCY AND LACTATION

Pregnancy: The available data on Tapinarof cream use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, subcutaneous administration of Tapinarof to pregnant rats and rabbits during the period of organogenesis resulted in no significant adverse effects at doses 268 and 16 times, respectively, the maximum recommended human dose (MRHD). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defects, loss, and other adverse outcomes.Lactation: No data are available regarding the presence of Tapinarof in human milk or the effects of Tapinarof on the breastfed infant or on milk production. Tapinarof was detected in rat offspring following subcutaneous administration to pregnant female rats which suggests that tapinarof was transferred into the milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Tapinarof cream and any potential adverse effects on the breastfed infant from Tapinarof cream or from the underlying maternal condition.

Pelelisa 0.01 | PRECAUTIONS & WARNINGS

For external use only. Avoid use in eyes, oral or intravaginal use. If there is any unusual allergic reaction with the use of Tapinarof, then treatment should be discontinued and appropriate therapy should be instituted.

Pelelisa 0.01 | THERAPEUTIC CLASS

Miscellaneous topical agents

Pelelisa 0.01 | STORAGE CONDITIONS

Do not store above 30°C. Keep in a dry place. Protect from light and keep out of the reach of children.